LONDON/ZURICH: Biotech fever is spreading to Europe from the US with a successful stock market debut for a cat allergy company in Britain seen as a bellwether that could help unlock listings in other countries including Switzerland and France.
The US is home to the world's leading biotech companies, resulting in an experienced pool of specialized US funds with a deep understanding of the sector's complexities and long development timelines.
Already a subscriber? Log in.
Subscribe to win RM50 Touch 'n Go e-Voucher! More Info
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!